Global footprint Cisbio is now part of PerkinElmer with facilities in France, the United States, Japan and China, offering opportunities to cross-sell diagnostics and drug discovery solutions across global markets.

HTRF leadership As a leader in homogeneous fluorescence detection with HTRF technology, there are opportunities to upsell complementary assay services, instrumentation, and assay development support to enhance high-throughput screening and in vitro diagnostic workflows.

Clinical and research demand Cisbio provides immunoassays for in vitro diagnostics focused on cancer, metabolic and autoimmune diseases, signaling potential sales of standardized kits, custom assay development, and service contracts to pharma, CROs, and clinical labs.

Mid-market fit With 51-200 employees and revenue in the mid tens of millions, Cisbio sits between smaller specialized labs and large biotech suppliers, presenting cross-sell and channel opportunities through PerkinElmer’s distribution and enterprise sales networks.

Funding and partnerships The combination of private funding signals and PerkinElmer backing, plus active engagement in global markets, suggests readiness for expanded collaboration, joint ventures, or co-developed assays and platforms to accelerate market adoption.